Stocks in focus: Easy Trip Planners IPO, Cipla, NMDC, Indian Oil, PVR, Reliance Home Finance

After gaining over 2.5 per cent in the previous week, BSE Sensex and Nifty 50 are set to start the week on a positive note on Monday

stocks in focus, Reliance home, NMDC

ICICI Bank, Infosys, among top large-cap stock picks in 2021 with over 13% potential upside

Indian share markets hit fresh record high yet again, with BSE Sensex ruling above 49,200 for the first time ever. The broader Nifty 50 index topped the crucial 14,450 level

stocks in focus, yes bank, maruti suzuki

Cipla shares: Analysts turn bullish on Cipla post Revlimid patent settlement; see nearly 30% rally

With Cipla having achieved a commanding market share in gProventil, US growth is now expected to be driven by market share gains from other Albuterol inhalers


Diwali technical stock picks: Buy these 5 shares for up to 30% rally in 3 months in Samvat 2077

Indian share markets rebounded sharply from March lows, and are now back to pre-COVID levels. Nifty 50 has rallied over 60 per cent from its 52-week low of 7511.

ICICI Bank, Cipla, Infosys, diwali

3 pharma stocks set to gain 25% as cardiac remains dominant therapy in Indian pharma market

According to the brokerage firm, Lupin, Glenmark, JB Chemicals, and Cipla are likely to gain market share among listed players.

UTI AMC, mazagon dock, IPO

Cipla shares hit new 52-week high, surge 128% since March; Morgan Stanley sees this much upside in stock

Cipla said that the company continues to closely monitor the impact of the coronavirus pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners

Stocks in focus: Glenmark Pharma, Cipla, Reliance Capital, HDFC Bank shares to remain in news today

Market sentiments would be swayed by global cues, development around geopolitical tensions, coronavirus cases, monthly F&O expiry and foreign fund movement

U.S. Stocks, Apple, Stock Split, iPhone maker, U.S. tech companies, U.S. tech stocks

Cipla, Ashok Leyland, Tata Chemicals, Escorts, agri stocks to remain in action today

Aarti Drugs, Cipla, Crompton Greaves, IIFL Securities, Nippon Life India Asset Management, Tata Chemicals and L&T Technology Services are among 12 companies that are scheduled to announce their March quarter earnings today.

Regeneron Pharmaceuticals, S&P 500, best performing stock, Netflix, Amazon,

Sun Pharma, Aurobindo Pharma among top stock picks from Pharma sector; CLSA sees gain up to 30%

Among pharma stocks, the top stock picks of CLSA are Sun Pharma, Cipla, Aurobindo Pharma and Cadila Healthcare, recommending a 'buy' rating on them

Cipla share price falls 5% after warning letter from US Food and Drug Administration

he USFDA had conducted an inspection at Cipla’s Goa facility in September last year. Cipla share price was down at Rs 406 on market opening.

Cipla board approves appointment of Dr Reddy’s Laboratories’ Kedar Upadhye as Global CFO

Drug firm Cipla today said its board has approved appointment of Kedar Upadhye as the company's Global Chief Financial Officer.

Delhi HC questions govt over urgency to ban over 300 FDC drugs

Additional Solicitor General was responding to the contentions of pharma companies like Pfizer, Glenmark, Procter and Gamble and Cipla

Delhi HC extends relief to pharma firms over drug ban

Several companies went to the Delhi High Court to try to get the ban lifted

11 stocks trending in Friday’s trade: Crompton Greaves, DLF and more

Healthcare majors, including Cipla, Lupin, Wockhardt, Glaxosmithkline and Mankind Pharma, on Thursday granted interim relief by Delhi High Court which stayed till March 21 the ban imposed by the Centre on sale of some of thei

Cipla invests additional $ 3mn in US’s Chase Pharmaceuticals

Cipla in May 2014 had invested $1.5 million to acquire 14.6 per cent stake in Chase Pharmaceuticals.


Cipla completes acquisition of generic businesses in US

The acquisition will provide a launch pad to introduce Cipla’s pipeline of products in respiratory and injectables, among others, in the coming years Cipla’s UK arm, Cipla (EU) has closed the transaction to acquire tw

Cipla posts PAT of Rs 343 crore in Q3 FY1516

Domestic sales reduced to Rs 1,194 crore Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2015 (Q3). Income from operations grew by 12.3 per cent to Rs 3,107 crore, up from Rs. 2

Cipla patriarch Y K Hamied increases stake in company to over 20 per cent

Acquires additional five per cent stake from his wife Farida Hamied In a move aimed at realignment of family shareholding, Cipla patriarch YK Hamied has increased his stake in the homegrown drug major to over 20 per cent by a

Cipla gets CCI nod to sell stake in consumer healthcare business

In November last year, the company signed an agreement to sell 26.11 per cent in Cipla Health to FIL Capital Investments (Mauritius) II Cipla has received approval from fair trade regulator CCI to sell about 26 per cent stake

SC admits Cipla’s plea for expert appointment in Hoffmann-La Roche patent row

In Nov, the Delhi HC, while holding Cipla guilty of infringing Roche’s patent over lung cancer drug Erlotinib, had held that its Erlocip violated the patent rights of Hoffman-La Roche

Top 10 stocks that trended in today’s trade: SpiceJet, Interglobe Aviation, Supreme Petrochem and more

SpiceJet shares closed 11.22 per cent up at Rs 78.80 after the company posted a net profit of Rs.238.39 crore in the December quarter, against a net loss of Rs.275.02 crore in the year-ago period.

Stocks in focus

Cipla announces new management council

Appoints Umang Vohra as its Global Chief Operating Officer Cipla announced the creation of a six member Management Council that will be the apex executive leadership team for the company. This is part of its ongoing transform

Cipla inks pact with US firm for Ropivacaine infusion system

Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India.

Cipla stake

Cipla launches anti-ageing skin care product Cutisera

Cutisera has been developed by Stempeutics Cipla has launched a novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult

Cipla ready to launch low-dose Efavirenz 400 mg

Studies found that the reduced dose of 400 mg Efavirenz was non-inferior to the standard dose of 600 mg Efavirenz dose

Cipla inks investment pact with FIL Capital Investment

No financial deals of the agreement were disclosed

Income Tax Calculator, Budget 2019, How to Calculate Income Tax


Stock Market

Most Read


Top News


Related Articles